Page last updated: 2024-11-12

gomisin-g

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID14992067
CHEMBL ID515928
MeSH IDM0320150

Synonyms (18)

Synonym
gomisin g
benzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxole-7,8-diol, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, 8-benzoate, (6s,7s,8s)-
CHEMBL515928
C17819
CS-3665
unii-6b4cv8t31x
6B4CV8T31X ,
(-)-gomisin g
62956-48-3
benzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole-7,8-diol, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, 8-benzoate, (6s,7s,8s,13as)-
HY-N0858
AKOS037514682
Q27264434
MS-29908
gomising
[(9s,10s,11s)-10-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-11-yl] benzoate
A868300
DTXSID601346778
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID380431Antiinflammatory activity against LPS-induced prostaglandin E2 production in mouse macrophages upto 25 ug/ml2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID380428Cytotoxicity against human KB cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID380425Cytotoxicity against african green monkey Vero cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID335887Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 100 mol ratio relative to TPA2002Journal of natural products, Sep, Volume: 65, Issue:9
Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation.
AID380424Cytotoxicity against human HL60 cells by XTT assay2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID380430Cytotoxicity against human SKOV3 cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID399882Antiviral activity against HIV2004Journal of natural products, Feb, Volume: 67, Issue:2
Current developments in the discovery and design of new drug candidates from plant natural product leads.
AID380423Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID492523Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV 3B2010Journal of natural products, Mar-26, Volume: 73, Issue:3
Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
AID335885Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 1000 mol ratio relative to TPA2002Journal of natural products, Sep, Volume: 65, Issue:9
Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation.
AID380429Cytotoxicity against human BT549 cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID470248Inhibition of 5 ug/ml PHA-stimulated human PBMC proliferation assessed as [3H]thymidine uptake at 100 uM after 3 days by scintillation counting2009Journal of natural products, Sep, Volume: 72, Issue:9
Oxygenated lignans from the fruits of Schisandra arisanensis.
AID404000Antiviral activity against HIV1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID1168387Inhibition of P-gp-mediated doxorubicin efflux in human HL60/MDR cells assessed as intracellular doxorubicin accumulation at 25 uM preincubated for 15 mins measured after 60 mins by flow cytometry2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID492522Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA2010Journal of natural products, Mar-26, Volume: 73, Issue:3
Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
AID335888Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 10 mol ratio relative to TPA2002Journal of natural products, Sep, Volume: 65, Issue:9
Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation.
AID380432Inhibition of COX2 in mouse macrophages2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID380427Cytotoxicity against human SK-MEL cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID380426Cytotoxicity against pig LLC-PK1 cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID335886Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 500 mol ratio relative to TPA2002Journal of natural products, Sep, Volume: 65, Issue:9
Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation.
AID470246Inhibition of human PBMC proliferation assessed as [3H]thymidine uptake at 100 uM after 3 days by scintillation counting2009Journal of natural products, Sep, Volume: 72, Issue:9
Oxygenated lignans from the fruits of Schisandra arisanensis.
AID470247Inhibition of 0.2 ug/ml PHA-stimulated human PBMC proliferation assessed as [3H]thymidine uptake at 100 uM after 3 days by scintillation counting2009Journal of natural products, Sep, Volume: 72, Issue:9
Oxygenated lignans from the fruits of Schisandra arisanensis.
AID335889Cytotoxicity against human Raji cells at 1000 mol ratio by trypan blue staining method2002Journal of natural products, Sep, Volume: 65, Issue:9
Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (42.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]